Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma

Journal of Pathology

Volumn 218, Issue 3, 2009, Pages 380-390

  Strickland, Laura A ^a   Ross, Jed ^a   Williams, Simon ^a   Ross, Sarajane ^a   Romero, Maria ^a   Spencer, Susan ^a   Erickson, Rich ^a   Sutcliffe, Julie ^b   Verbeke, Caroline ^c   Polakis, Paul ^a   Van Bruggen, Nicholas ^a   Koeppen, Hartmut ^a  

^a GENENTECH INC   (United States)

^b University of California   (United States)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Antibody drug conjugate; CEACAM6; DM1; Pancreatic adenocarcinoma; Preclinical safety evaluation

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACACA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE MICROARRAY;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL ADHESION MOLECULES; DRUG EVALUATION, PRECLINICAL; FEASIBILITY STUDIES; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOCONJUGATES; MACACA FASCICULARIS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEUTROPHIL ACTIVATION; PANCREATIC NEOPLASMS;

EID: 67650085253     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2545     Document Type: Article

References (44)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-1057.
3. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004;5:541-549.
4. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Gastroenterol Rep 2004;6:119-125.
5. Beauchemin N, Draber P, Dveksler G, Gold P, Grey-Owen S, Grunert F, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999;252:243-249.
6. Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res 2005;65:8809-8817.
7. Duxbury MS, Ito H, Ashley SW, Whang EE. CEACAM6 crosslinking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. J Biol Chem 2004;279:23176- 23182.
8. Duxbury MS, Ito H, Ashley SW, Whang EE. c-Src-dependent cross-talk between CEACAM6 and αvβ3 integrin enhances pancreatic adenocarcinoma cell adhesion to extracellular matrix components. Biochem Biophys Res Commun 2004;317:133-141.
9. Duxbury MS, Ito H, Benoit E, Ashley SW, Whang EE. CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer 2004;91:1384-1390.
10. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene 2004;23:5834-5842.
11. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004;23:465-473.
12. Ordonez C, Screaton RA, Ilantzis C, Stanners CP. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res 2000;60:3419-3424.
13. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 2004;64:3987-3993.
14. Duxbury MS, Ito H, Ashley SW, Whang EE. CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma. Biochem Biophys Res Commun 2004;317:837-843.
15. Duxbury MS, Matros E, Clancy T, Bailey G, Doff M, Zinner MJ, et al. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg 2005;241:491-496.
16. Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg 2004;240:667-674; discussion, 675-666.
17. Audette M, Buchegger F, Schreyer M, Mach JP. Monoclonal antibody against carcinoembryonic antigen (CEA) identifies two new forms of crossreacting antigens of molecular weight 90 000 and 160 000 in normal granulocytes. Mol Immunol 1987;24:1177-1186.
18. Buchegger F, Schreyer M, Carrel S, Mach JP. Monoclonal antibodies identify a CEA crossreacting antigen of 95 kDa (NCA-95) distinct in antigenicity and tissue distribution from the previously described NCA of 55 kDa. Int J Cancer 1984;33:643-649.
19. Burtin P, Quan PC, Sabine MC. Nonspecific cross reacting antigen as a marker for human polymorphs, macrophages and monocytes. Nature 1975;255:714-716.
20. von Kleist S, Chavanel G, Burtin P. Identification of an antigen from normal human tissue that crossreacts with the carcinoembryonic antigen. Proc Natl Acad Sci USA 1972;69:2492-2494.
21. Burtin P, Flandrin G, Fondaneche MC. Presence of NCA (nonspecific cross-reacting antigen) in the cells of the human granulocyte series. Blood Cells 1980;6:263-278.
22. Gadler F, Wahren B. Decrease of a normal colon and granulocyte antigen (NCA) in whole lysed blood of myelosuppressed patients. Scand J Haematol 1983;30:297-302.
23. Kuroki M, Matsuo Y, Kinugasa T, Matsuoka Y. Three different NCA species, CGM6/CD67, NCA-95, and NCA-90, are comprised in the major 90-100 kDa band of granulocyte NCA detectable upon SDS-polyacrylamide gel electrophoresis. Biochem Biophys Res Commun 1992;182:501-506.
24. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
25. Hongo JA, Mora-Worms M, Lucas C, Fendly BM. Development and characterization of murine monoclonal antibodies to the latency-associated peptide of transforming growth factor β1. Hybridoma 1995;14:253-260.
26. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497.
27. 64Cu- labelled α-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem 2007;18:765- 772.
28. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-131.
29. Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 1996;93:8618-8623.
30. Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 2007;67:4924-4932.
31. Robinson JM, Badwey JA, Karnovsky ML, Karnovsky MJ. Release of superoxide and change in morphology by neutrophils in response to phorbol esters: antagonism by inhibitors of calcium-binding proteins. J Cell Biol 1985;101:1052-1058.
32. - progenitor cells. Blood 1991;77:1218-1227.
33. Gardner-Thorpe J, Ito H, Ashley SW, Whang EE. Differential display of expressed genes in pancreatic cancer cells. Biochem Biophys Res Commun 2002;293:391-395.
34. Ilantzis C, DeMarte L, Screaton RA, Stanners CP. Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia 2002;4:151-163.
35. Jantscheff P, Terracciano L, Lowy A, Glatz-Krieger K, Grunert F, Micheel B, et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol 2003;21:3638-3646.
36. Kodera Y, Isobe K, Yamauchi M, Satta T, Hasegawa T, Oikawa S, et al. Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation. Br J Cancer 1993;68:130-136.
37. Scholzel S, Zimmermann W, Schwarzkopf G, Grunert F, Rogaczewski B, Thompson J. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol 2000;156:595-605.
38. Chan CH, Camacho-Leal P, Stanners CP. Colorectal hyperplasia and dysplasia due to human carcinoembryonic antigen (CEA) family member expression in transgenic mice. PLoS ONE 2007;2:e1353.
39. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al. Yttrium-90-labelled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-470.
40. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002;29:9-16.
41. Krop IE BM, Modi S, Rabbee N, Girish S, Tibbitts J, Holden SN, et al. A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer. San Antonio Breast Cancer Symposium, 2007; San Antonio, TX, USA.
42. McCann J, Fossella FV, Villalona-Calero MA, Tolcher AW, Fidias P, Raju R, et al. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma. ASCO Meeting Abstracts 2007;25:18084.
43. Chen Y, Zheng B, Robbins DH, Lewin DN, Mikhitarian K, Graham A, et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer 2007;120:1511-1517.
44. Dunphy CH, Polski JM, Evans HL, Gardner LJ. Evaluation of bone marrow specimens with acute myelogenous leukemia for CD34, CD15, CD117, and myeloperoxidase. Arch Pathol Lab Med 2001;125:1063-1069.